<DOC>
	<DOCNO>NCT02941367</DOCNO>
	<brief_summary>Primary Objective : To compare safety , term percentage patient symptomatic document hypoglycemia Ramadan fast , lixisenatide versus sulfonylurea ( SU ) . Secondary Objectives : - To assess effect lixisenatide versus SU : - Changes glycemic control ; - Changes body weight . - To assess overall safety lixisenatide SU .</brief_summary>
	<brief_title>Safety Assessment Lyxumia ( Lixisenatide ) Sulfonylurea Add-on Treatment Basal Insulin Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect Fast During Ramadan</brief_title>
	<detailed_description>The total study duration per patient minimum 12 week maximum 22 week ( 2 week screen period + 8-12 week pre-Ramadan period + 29-30 day Ramadan + 0 4 week post-Ramadan period ) . This phase 3b study Kingdom Saudi Arabia Bangladesh ( instead phase 4 country ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criterion : Patients type 2 diabetes mellitus , diagnose least 1 year time screen visit , insufficiently control basal insulin + SU ( ≤50 % max allow dose ) ±1 oral antidiabetic ( OAD ) drug . Patients express intention fast Ramadan . Signed informed consent . Exclusion criterion : At time screen age &lt; legal age majority . Glycated hemoglobin ( HbA1c ) screen visit : &lt; 7.5 % &gt; 10 % . Body mass index ( BMI ) &lt; 20kg/m^2 . Treatment basal insulin le 6 month prior screen . Prior antidiabetic medication ( basal insulin OADs ) stable dose ( eg , medication , frequency &lt; 20 % dose change ) last 8 week prior screen . Previous treatment short rapid act insulin short term use ( ≤10 day ) relation hospitalization acute illness last 6 month prior screen . Any discontinuation glucagon like peptide1 receptor agonist ( GLP1 RA ) due safety/tolerability issue lack efficacy . Patient willing perform selfmonitored plasma glucose ( SMPG ) require protocol follow instruction provide . Type 1 , gestational secondary diabetes . History diabetic ketoacidosis . History hypoglycemia unawareness . Any medical contraindication sustain safe fasting . Pregnant breastfeed woman . Women childbearing potential ( WOCB ) protect highly effective contraceptive method ( ) birth control and/or unwilling unable test pregnancy . Known hypersensitivity/intolerance lixisenatide ( Lyxumia ) excipients . All contraindication comparator protocol mandate background therapy warning/precaution use ( appropriate ) display respective National Product Labeling . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>